Allianz Asset Management GmbH Has $59 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Allianz Asset Management GmbH lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 100.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 218,503 shares of the biopharmaceutical company's stock after acquiring an additional 109,632 shares during the quarter. Allianz Asset Management GmbH owned about 0.17% of Alnylam Pharmaceuticals worth $59,000,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $275,000. GAMMA Investing LLC increased its stake in Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after purchasing an additional 77 shares in the last quarter. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $243,000. Finally, Silvercrest Asset Management Group LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $1,151,000. 92.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ALNY shares. Redburn Atlantic started coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a "buy" rating and a $353.00 price target on the stock. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Chardan Capital increased their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Truist Financial started coverage on Alnylam Pharmaceuticals in a report on Monday. They set a "buy" rating and a $385.00 price target on the stock. Finally, JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-three have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $347.75.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $0.94 on Friday, reaching $328.94. 332,196 shares of the stock were exchanged, compared to its average volume of 892,431. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $333.70. The firm has a fifty day moving average price of $310.69 and a two-hundred day moving average price of $274.03. The stock has a market cap of $42.89 billion, a PE ratio of -157.12 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.16) EPS. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the transaction, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.